摘要
目的研究COX-2和HER-2在非小细胞肺癌(NSCLC)组织中的表达及其临床意义。方法采用免疫组织化学法检测了68例非小细胞肺癌组织中COX-2和HER-2的表达水平,分析两者与临床病理参数之间的关系以及分析两者之间的相互关系。结果非小细胞肺癌中COX-2阳性表达率为54/68(79.41%),COX-2的高表达与病理类型及TNM分期相关(P<0.05);HER-2阳性表达率为26/68(38.24%),HER-2的表达与年龄相关(P<0.05)。HER-2与COX-2的表达强度之间呈显著正相关(r=0.2486,P=0.041)。HER-2阳性/COX-2高表达的NSCLC临床分期晚、淋巴结转移率高。结论COX-2在NSCLC中高水平表达并与HER-2密切相关,检测COX-2与HER-2的表达对NSCLC预后的判断可能具有重要价值。
Objective To study the expression of cyclooxygenase-2(COX-2) and HER-2 in non-small cell lung cancer(NSCLC) and their clinical significance. Methods The expression of COX-2 and HER-2 proteins in 68 cases of non-small cell lung cancer were detected by using immunohistochemistry staining and the relationship between COX-2 and HER-2 was analyzed together with the clinicopathologic characteristics. Results Fifty-four cases of 68(79.41% ) NSCLC specimens were positive for COX-2. High expression of COX-2 was correlated with histological type and TNM stage(P〈0.05). Twenty-six cases of 68(38.24% ) NSCLC samples were positive for HER- 2, which was associated with age (P〈0. 05). The expression of COX-2 was closely related to the expression of HER-2( r = 0. 2486, P = 0. 041). HER-2 +/high COX-2 tumours proved to have later stage and higher lymph node metastasis. Conclusion The results indicate that COX-2 highly expresses in NSCLC and has a closely relation to the the expression of HER-2. The expression of COX -2 and HER-2 might have great significance in evaluating prognosis.
出处
《实用临床医药杂志》
CAS
2009年第7期35-38,41,共5页
Journal of Clinical Medicine in Practice